DRD2 and adenoma: Both Wurth et al. and Peverelli et al. studies compared, in adenoma tissues and in PASC-enriched spheroids, the expression of somatostatin (SSTR) and dopamine (D2R, dopamine receptor type 2) receptors, which are targeted by currently used pharmacological treatments (i.e., SSTR2 and SSTR5, which are activated by lanreotide and octreotide, and D2R, activated by cabergoline) (77, 78).